UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

See

Instruction 1(b).

1. Name and Address of Reporting Person*PFIZER INC

(Last)

(First)

(Middle)

235 E 42ND ST

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol

ICAGEN INC

[ ICGN ]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director

10% Owner

Officer (give title below)

Other (specify below)

3. Date of Earliest Transaction

(Month/Day/Year)

10/27/2011

4. If Amendment, Date of Original Filed

(Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr.

3)

2. Transaction Date

(Month/Day/Year)

2A. Deemed Execution Date, if any

(Month/Day/Year)

3. Transaction Code (Instr.

8)

4. Securities Acquired (A) or Disposed Of (D) (Instr.

3, 4 and 5)

5.

Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.

3 and 4)

6. Ownership Form: Direct (D) or Indirect (I) (Instr.

4)

7. Nature of Indirect Beneficial Ownership (Instr.

4)

Code

Amount

(A) or (D)

Price

Common Stock

10/27/2011

2,743,269(1)

$6

100(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr.

3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date

(Month/Day/Year)

3A. Deemed Execution Date, if any

(Month/Day/Year)

4. Transaction Code (Instr.

8)

5.

Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.

3, 4 and 5)

6. Date Exercisable and Expiration Date

(Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr.

3 and 4)

8. Price of Derivative Security (Instr.

5)

9.

Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.

4)

10. Ownership Form: Direct (D) or Indirect (I) (Instr.

4)

11. Nature of Indirect Beneficial Ownership (Instr.

4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

1. Name and Address of Reporting Person*PFIZER INC

(Last)

(First)

(Middle)

235 E 42ND ST

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director

10% Owner

Officer (give title below)

Other (specify below)

1. Name and Address of Reporting Person*Eclipse Acquisition Corp.

(Last)

(First)

(Middle)

235 EAST 42ND ST.

MS 235/19/2

(Street)

NEW YORK

NY

10017

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director

10% Owner

Officer (give title below)

Other (specify below)

Explanation of Responses:

1. This amount reflects all of the outstanding shares of Icagen, Inc. ("Icagen") not owned by Pfizer Inc. ("Pfizer") and Eclipse Acquisition Corp. On October 27, 2011, Eclipse Acquisition Corp. was merged with and into Icagen with Icagen continuing as the surviving corporation and a wholly-owned subsidiary of Pfizer. At the effective time of the merger, these shares of common stock were cancelled and ceased to exist.

2. Prior to the merger, Pfizer held 100 shares of common stock, $0.01 par value per share, of Eclipse Acquisition Corp., which represented all of the issued and outstanding capital stock of Eclipse Acquisition Corp. At the effective time of the merger, each share of Eclipse Acquisition Corp. was converted into one share of common stock of Icagen, resulting in the acquisition by Pfizer of 100% of the equity interest of Icagen.

/s/Bryan Supran, Sr. Vice President & Associate General Counsel - Pfizer Inc.

11/02/2011

/s/Andrew Muratore, Vice President & Secretary - Eclipse Acquisition Corp.

11/02/2011

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person,

see

Instruction

(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations

See

18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,

see

Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.